2026-02-24
GLP-1 Agonists and Aging: Metabolic Benefits, Cardiovascular Evidence, and Longevity Implications
GLP-1 receptor agonists like semaglutide have demonstrated cardiovascular and metabolic benefits beyond weight reduction. This review covers the mechanistic basis, major trial evidence, and the open questions about their role in longevity medicine.
2026-02-24
Sleep Architecture in Aging: Why Deep Sleep Declines and How to Partially Restore It
Slow-wave sleep (deep sleep) declines approximately 2% per decade from early adulthood, dropping from roughly 20% of total sleep in young adults to under 5% in adults over 70. This decline is not simply reduced sleep duration — it represents a fundamental change in sleep architecture with consequences for metabolic health, memory consolidation, and cellular repair.
2026-02-24
VO2max and Cardiorespiratory Fitness: Why It Predicts Longevity and How to Improve It
VO2max is one of the strongest independent predictors of all-cause mortality. This review covers what VO2max measures, how it declines with age, and the training protocols with the best evidence for improving it.
2026-02-23
Blood Sugar and Insulin Resistance: Supplement Protocol, Monitoring, and Evidence Summary
Insulin resistance precedes type 2 diabetes by years and independently drives cardiovascular risk, cognitive decline, and accelerated aging. Berberine, magnesium, alpha-lipoic acid, and chromium have the best evidence among supplements. This protocol integrates the strongest interventions with clear monitoring markers.
2026-02-23
Periodontal Disease and Aging: The Overlooked Systemic Risk
Periodontal disease is a chronic inflammatory condition linked to cardiovascular disease, diabetes, and cognitive decline. Here is what the evidence shows about management beyond brushing.